Dr. Howard is an experienced CEO who has led several successful life-sciences and biotechnology companies, both private and public.
Today Russell works in Sydney with NeuClone, dedicated to bringing affordable biosimilar monoclonal antibodies to the world, and Genome. One where whole genome sequencing is being commercialised to provide new products and services based on personalised medicine
Most recently, Russell served as CEO of Maxygen Inc, a publicly traded company he founded and led through its IPO (NASDAQ: MAXY), many corporate partnerships, and sale of spin-off companies. While he was CEO at Maxygen, the company raised over $700M in investment and $100M in Federal funds. At Maxygen Dr. Howard created and spun out the biofuels company Codexis and served on its Board of Directors until 2009. Codexis went public in 2010 (NASDAQ: CDXS). Previously Russell served as President and Scientific Director of Affymax Inc.. Dr. Howard has published over 140 peer-reviewed scientific publications, is the recipient of numerous awards and honors and serves on the board of several companies and foundations in the U.S. and overseas.